top of page
  • Active, not recruiting

NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

f isatuximab administered subcutaneously (SC)

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

  • To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)

  • To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device.

  • To evaluate the pharmacokinetics (PK) of SC and IV isatuximab


Sponsor

 

ClinicalTrials.gov Identifier: NCT05405166

Official Title: A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

First Posted : August 6, 2019

Click here to see details on ClinicalTrials.gov

 


 

Drug: isatuximab SAR650984 IV

Drug: pomalidomide

Drug: dexamethasone

Drug: isatuximab SAR650984 SC

Device: Investigational injector device

 

Locations

United States, Arizona

United States, California

United States, Ohio

Australia, New South Wales

Australia, Victoria

Europe

Asia

Belgium

France

Japan

Spain


Comments


Posts Archive
bottom of page